GLP-3 (RT) 10mg
LatestLOT RT0004
99.86%HPLC purity · meets spec
- Labeled
- 10mg
- Measured
- 10.4mg
- Identity
- Confirmed
- Heavy metals
- Not Detected
- Sterility
- No Growth
- Endotoxin
- < 0.05 EU/mL
- Tested
- Jul 30, 2026
8 assays passed · ISO/IEC 17025 accredited
Triple-Action Metabolic Compound
GLP-3 (RT)
LY3437943GLP-3
A 39-amino acid triple agonist peptide targeting GIP, GLP-1, and glucagon receptors, studied for metabolic regulation and body composition in clinical studies. Premium Direct-Supply Peptide.
MassChoose an option
Quantity
From$109
Fast, protected deliveryTracked USA shipping with discreet packaging.
Tracked USA delivery
Free shipment protection
Priority shipping available
Verified Test Results
Every batch, independently verified.
Each batch is analyzed by an ISO/IEC 17025 accredited third-party laboratory. The report below reflects the identity, purity and full-panel specification data reported by the lab.
ILSILS LaboratoriesCertificate of Analysis≥99%Purity by HPLC
ISO 17025 Accredited8× Tested
ParameterResultMethodSpecification
Peptide Purity (HPLC)99.86%HPLC>= 95%
Net Peptide Content10.4mgHPLCReport
Identity (HPLC)ConfirmedHPLCMeets spec
AppearanceGoodVisualMeets spec
Fentanyl ScreenNot DetectedImmunoassayPass
Heavy Metals (ICP-MS)Not DetectedICP-MSPass
Sterility (PCR)No GrowthPCRPass
Endotoxin (USP <85>)< 0.05 EU/mLUSP <85>Reported
Third-Party Verified
Certificate of Analysis
Every lot is HPLC-tested at an ISO/IEC 17025-accredited lab. Open any batch's certificate below.
Frequently Paired Products
Products commonly selected alongside this item
Compound Information
Technical specifications
MOLECULAR PROFILE
What Is GLP-3 (RT)?
- Type
- Synthetic peptide
- CAS Number
- 2381089-83-2
- Molecular Weight
- 4,731 g/mol
- Amino Acids
- 39
- Fatty Acid Chain
- C20 diacid
STORAGE REQUIREMENTS
Stability Information
Avoid freeze/thaw cyclesProtect from lightKeep refrigerated
Lyophilized (powder)-20°C24+ months
Reconstituted2-8°C~30 days
Product Guides & References
Verified publications and source documentation
NEW ENGLAND JOURNAL OF MEDICINE
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023•DOI: 10.1056/NEJMoa2301972Jastreboff AM, et al.
View Source THE LANCETGLP-3 (RT) for People with Type 2 Diabetes — A Phase 2 Trial
2023Rosenstock J, et al.
View Source NATURE MEDICINEGLP-3 (RT) for Metabolic Dysfunction-Associated Steatotic Liver Disease
2024Sanyal AJ, et al.
View Source LANCET DIABETES & ENDOCRINOLOGYEffects of GLP-3 (RT) on Body Composition
2025Coskun T, et al.
View Source PUBMED CENTRALTriple Agonism Based Therapies for Obesity
2025
View Source PUBMED CENTRALGLP-3 (RT) — A Game Changer in Obesity Pharmacotherapy
2025
View Source PUBMED CENTRALEfficacy and Safety of GLP-3 (RT) — Systematic Review & Meta-Analysis
2024
View Source ELI LILLYTRIUMPH-4 Phase 3 Trial Results
2025
View Source NATURE CELL DISCOVERYStructural Analysis of Incretin Receptor Agonists
2024
View Source PUBCHEM DATABASE
